Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305731 | 1.00 | HDAC1 (0.45) | HDAC1HPGDRAB9AHTTHDAC8 | |
| SCHEMBL29488468 | 1.00 | HDAC1 (0.45) | HDAC1HPGDRAB9AHTTHDAC8 | |
| SCHEMBL1305316 | 0.92 | HPGD (0.44) | HPGDRAB9AHTTSIGMAR1SLC6A5 | |
| SCHEMBL1305319 | 0.92 | HPGD (0.44) | HPGDRAB9AHTTSIGMAR1SLC6A5 | |
| SCHEMBL1306172 | 0.91 | SIGMAR1 (0.41) | HPGDRAB9AHTTSIGMAR1SLC6A5 | |
| SCHEMBL1306171 | 0.91 | SIGMAR1 (0.41) | HPGDRAB9AHTTSIGMAR1SLC6A5 | |
| SCHEMBL1306649 | 0.88 | HPGD (0.46) | HPGDRAB9AHTTSLC6A5TP53 | |
| SCHEMBL1306644 | 0.88 | HPGD (0.46) | HPGDRAB9AHTTSLC6A5TP53 | |
| SCHEMBL1307239 | 0.88 | SLC6A5 (0.38) | HDAC1HPGDRAB9AHTTSIGMAR1 | |
| SCHEMBL1307246 | 0.88 | SLC6A5 (0.38) | HDAC1HPGDRAB9AHTTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | claimed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | claimed |
| EP-4026544-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | Crystalgenomics, Inc. (KR) | 2022-07-13 | — | — | EP | claimed |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | CRYSTALGENOMICS, INC. (KR) | 2021-11-11 | — | — | US | claimed |
| EP-3875081-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | Crystalgenomics, Inc. (KR) | 2021-09-08 | — | — | EP | claimed |
| WO-2021045392-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | 크리스탈지노믹스(주) | 2021-03-11 | — | — | WO | claimed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | claimed |
| EP-3640239-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2020-04-22 | — | — | EP | claimed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | claimed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | claimed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | claimed |
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | CRYSTALGENOMICS, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4155292-A1 | METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE | Crystalgenomics, Inc. (KR) | 2023-03-29 | — | — | EP | disclosed |
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | CRYSTALGENOMICS, INC. (KR) | 2022-09-15 | — | — | US | disclosed |
| WO-2022177054-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | 크리스탈지노믹스(주) | 2022-08-25 | — | — | WO | disclosed |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2020-09-10 | — | — | US | disclosed |
| EP-3640239-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2020-04-22 | — | — | EP | disclosed |
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-8053435-B2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287993-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY | PDCD1, HDAC1, HDAC5 | HDAC1 2/4885HPGD 1284/4885RAB9A 3274/4885 |
| US-20210346321-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR | AGPAT5, NOTUM, HADH | HDAC1 2152/4885HPGD 1142/4885RAB9A 4312/4885 |
| US-11655207-B2 | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same | DOHH, CYP51A1, ASAH2 | HDAC1 2369/4885HPGD 258/4885RAB9A 1905/4885 |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HPGD 413/4885RAB9A 3470/4885 |
| US-20200283371-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME | DOHH, CYP51A1, CYP46A1 | HDAC1 2705/4885HPGD 210/4885RAB9A 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.